Relay Therapeutics (RLAY) Preferred Stock Liabilities (2019 - 2020)
Relay Therapeutics (RLAY) reported Preferred Stock Liabilities of $537.8 million for Q2 2020, little changed quarter-over-quarter from $537.8 million in Q4 2019.
Relay Therapeutics (RLAY) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Relay Therapeutics (RLAY) has 2 years of Preferred Stock Liabilities data on file, last reported at $537.8 million in Q2 2020.
- Preferred Stock Liabilities for Q2 2020 came in at $537.8 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2020 was $537.8 million (changed N/A YoY), and the FY2019 annual result was $537.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $537.8 million in Q2 2020 per RLAY's latest filing, from $537.8 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $537.8 million in Q4 2019 and troughed at $537.8 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 537.78 Mn |
| Dec 31, 2019 | 537.78 Mn |